Moderna to boost global Covid-19 vaccine manufacturing capacity
Moderna has announced plans to increase its global manufacturing capacity for Covid-19 vaccine by making additional capital investments.
Moderna has announced plans to increase its global manufacturing capacity for Covid-19 vaccine by making additional capital investments.
Pfizer and BioNTech have entered into an agreement with the European Commission (EC) to supply an additional 200 million doses of their Covid-19 vaccine.
Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine manufacturing capability.
Ocugen, a Pennsylvania-based pharmaceutical company, has signed an agreement with Bharat Biotech, an Indian pharma developer of COVAXIN, a Covid-19 vaccine, to distribute the vaccine in the US.
WuXi STA, a subsidiary of Chinese pharmaceutical company WuXi AppTec, has agreed to buy the Couvet, Switzerland-based manufacturing facility from Bristol Myers Squibb.
AstraZeneca has secured a conditional marketing authorisation for its Covid-19 vaccine in the European Union (EU) for active immunisation in individuals aged 18 years and above.
Humanigen has announced an expansion to the Cooperative Research and Development Agreement (CRADA) with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
Akron Biotechnology (Akron Biotech) has signed an exclusive global agreement with Swiss-based Octapharma, to manufacture virally inactivated Human AB Serum for the cell therapy market.
Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the Company’s plans for the buildout of its new Research and Development (R&D) and Chemistry, Manufacturing and Controls (CMC) operation which will also serve as the Company’s new headquarters in Cranbury, New Jersey.
Akston Biosciences has entered into a strategic partnership with US-based contract research, development, and manufacturing organisation (CRDMO) LakePharma to manufacture second-generation Covid-19 vaccine.